A novel inhaled metered cryospray treatment for COPD demonstrated clinically meaningful improvements in quality of life and reduced severe exacerbations by 38.4% compared to control in a 210-patient randomized trial, offering a new therapeutic option for patients with chronic bronchitis who remain symptomatic despite optimal medical therapy.
- The SPRAY-CB trial enrolled 210 patients with moderate-to-severe COPD and chronic bronchitis across the United States and United Kingdom.
- Metered CryoSpray (MCS) treatment achieved a 5.9-point improvement in respiratory quality of life scores, exceeding the 4-point clinical significance threshold.
- MCS-treated patients experienced a 38.4% relative reduction in severe COPD exacerbations compared with the control group.
- The treatment also demonstrated 3.4-point greater improvement in COPD Assessment Test scores, surpassing the established 2-point meaningful benefit threshold.
- Results address a significant unmet need for patients who remain symptomatic despite receiving optimal medical therapy for COPD.
A novel inhaled treatment for COPD is showing promising results in a randomized, blind, sham-controlled trial. The results are detailed in the paper, “Metered-Dose Liquid Nitrogen Cryospray for Chronic Bronchitis: Results From the Prospective, Sham-Controlled Trial (SPRAY-CB),” which was published in the American Journal of Respiratory and Critical Care.
The SPRAY-CB trial randomized 210 patients with moderate-to-severe COPD and symptomatic chronic bronchitis in the United States and the United Kingdom. The patients were highly symptomatic despite optimal medical therapy.
The study found that those treated with CSA Medical’s RejuvenAir Metered CryoSpray (MCS) had “significantly greater improvement” in scores using the St. George’s Respiratory Questionnaire (SGRQ) compared to those in the control group.
According to a press release, the trial met its primary effectiveness endpoint. At 12 months, MCS-treated patients demonstrated a 5.9-point greater improvement in the SGRQ score compared to the control group. This exceeded the 4-point threshold for a clinically meaningful benefit.
MCS-treated patients also demonstrated a 3.4-point greater improvement in COPD Assessment Test scores compared with the control group, exceeding the established 2-point threshold.
The MCS treatment was also associated with fewer severe COPD exacerbations, with patients receiving the treatment experiencing a 38.4% relative reduction in the incidence rate of severe exacerbations compared with control.
“Patients enrolled in SPRAY-CB remained highly symptomatic despite receiving optimal medical therapy, underscoring the significant unmet need in chronic bronchitis,” said Gerard Criner, MD, chair and professor of thoracic medicine and surgery at Lewis Katz School of Medicine at Temple University in Philadelphia and lead author of the study. “Metered CryoSpray demonstrated clinically meaningful improvements in quality of live and overall COPD symptoms through 12 months. These findings, together with the lower incidence of severe COPD exacerbations observed with MCS, support the potential for a bronchoscopic therapy that directly targets airways affected by chronic bronchitis to provide an important new treatment option for these patients.”
